However, galectin-3 was the only biomarker associated with an increased risk of developing HF and death in T2DM patients (HR 2.14 (1.18–3.91), p = 0.013), along with age (HR 1.10 (1.04–1.15), p < 0.001), atrial fibrillation (HR 8.84 (1.07–73.7), p = 0.043), and treatment with anticoagulants (HR 33.32 (2.46–450.5), p = 0.008), aldosterone receptor blockers (HR 7.59 (1.66–34.7), p = 0.009) and nitrates (HR 4.05 (1.20–13.6), p = 0.024). Here, LGALS3 is linked to type 2 diabetes mellitus.